Ascendis Pharma A/S (NASDAQ:ASND – Free Report) – Analysts at Wedbush lifted their FY2026 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research note issued to investors on Wednesday, November 8th. Wedbush analyst A. Argyrides now expects that the biotechnology company will earn $4.12 per share for the year, up from their prior forecast of $3.83. Wedbush has a “Outperform” rating and a $192.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($9.75) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s FY2027 earnings at $15.20 EPS.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last issued its quarterly earnings results on Tuesday, September 5th. The biotechnology company reported ($2.35) EPS for the quarter, topping analysts’ consensus estimates of ($2.68) by $0.33. The business had revenue of $51.59 million during the quarter, compared to analysts’ expectations of $41.73 million. Ascendis Pharma A/S had a negative return on equity of 570.61% and a negative net margin of 391.76%.
Ascendis Pharma A/S Stock Performance
NASDAQ:ASND opened at $90.28 on Friday. The stock has a market capitalization of $5.21 billion, a P/E ratio of -7.94 and a beta of 0.48. The stock has a 50-day moving average price of $93.99 and a 200 day moving average price of $91.82. The company has a current ratio of 3.44, a quick ratio of 2.65 and a debt-to-equity ratio of 7.39. Ascendis Pharma A/S has a 12-month low of $64.33 and a 12-month high of $134.52.
Institutional Trading of Ascendis Pharma A/S
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. raised its holdings in Ascendis Pharma A/S by 61.3% in the 2nd quarter. RA Capital Management L.P. now owns 11,225,357 shares of the biotechnology company’s stock worth $1,001,863,000 after purchasing an additional 4,268,178 shares during the period. Goldman Sachs Group Inc. grew its position in Ascendis Pharma A/S by 3,024.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,754,458 shares of the biotechnology company’s stock worth $205,903,000 after acquiring an additional 1,698,302 shares during the period. T. Rowe Price Investment Management Inc. lifted its stake in Ascendis Pharma A/S by 39.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,828,267 shares of the biotechnology company’s stock worth $345,417,000 after purchasing an additional 796,087 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Ascendis Pharma A/S by 14.6% in the first quarter. Wellington Management Group LLP now owns 4,665,579 shares of the biotechnology company’s stock valued at $547,552,000 after acquiring an additional 594,855 shares in the last quarter. Finally, Capital International Investors purchased a new position in Ascendis Pharma A/S in the first quarter valued at $28,894,000.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.
- Five stocks we like better than Ascendis Pharma A/S
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 11/6 – 11/10
- The How And Why of Investing in Oil Stocks
- Data giants MongoDB and Snowflake just got upgraded
- Your Comprehensive Guide to Investing in Bank Stocks
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.